Equity Research, Broker Reports, and media content on C4X Discovery Holdings PLC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about C4X Discovery Holdings PLC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 28 Apr 22
C4X Discovery Holdings PLC on expanding its portfolio
c4x-discovery-holdings-plc-on-expanding-its-portfolio
  • 13 Dec 21
C4X Discovery Holdings highlight their good position for advancement and expansion in current year
c4x-discovery-holdings-highlight-their-good-position-for-advancement-and-expansion-in-current-year
  • 12 Apr 21
SP Angel Healthcare Conditions- 12-04-2021


Companies: Novacyt SAS (ALNOV:PAR)C4X Discovery Holdings PLC (C4XD:LON)
  • 12 Apr 21
Small Cap Feast

Semper Fortis Esports* recently announced its intention to IPO onto the Access Segment of the Aquis Stock Exchange Growth Market. Semper is a multi-operational Esports organisation focusing on gaming technology solutions, brand enhancement and high growth team infrastructures. The company plans to raise £2.5m to develop their three core areas of establishing an esports team, forming partnerships with brands for sponsorship and B2B consultancy services. The Board are highly experienced in spor

Companies: ADME ELIX DEV PPC TXP THR ATM FFWD C4XD IOG

  • 10 Dec 20
C4X Discovery Holdings' say four programs 'in great shape to start finding right partner for each'
c4x-discovery-holdings-say-four-programs-in-great-shape-to-start-finding-right-partner-for-each-
  • 10 Dec 20
C4X Discovery Holdings say four programs 'in great shape to start finding right partner for each'
c4x-discovery-holdings-say-four-programs-in-great-shape-to-start-finding-right-partner-for-each-
  • 10 Dec 20
C4X Discovery Holdings says four programs "in great shape to start finding right partner for each"
c4x-discovery-holdings-says-four-programs-in-great-shape-to-start-finding-right-partner-for-each-
  • 10 Dec 20
C4X Discovery Holdings says strong progress across the portfolio as commercial discussions continue
c4x-discovery-holdings-says-strong-progress-across-the-portfolio-as-commercial-discussions-continue
  • 25 Aug 20
C4X Discovery CEO welcomes start of Indivior trial and outlines new coronavirus venture
c4x-discovery-ceo-welcomes-start-of-indivior-trial-and-outlines-new-coronavirus-venture
  • 25 Aug 20
SP Angel Healthcare Conditions

C4X Discovery (C4XD.L): Business update

Companies: C4X Discovery Holdings PLC
  • 29 Apr 20
C4X Discovery 'progressing well' with development of its programmes and partner discussions
c4x-discovery-progressing-well-with-development-of-its-programmes-and-partner-discussions
  • 07 Jan 20
SP Angel Healthcare Conditions

C4X Discovery Holdings plc (C4XD.L): Full year results

Companies: C4X Discovery Holdings PLC
  • 25 Oct 19
C4X Discovery fully cashed up and sees big potential for its 'blockbuster molecules'
c4x-discovery-fully-cashed-up-and-sees-big-potential-for-its-blockbuster-molecules-
  • 02 Oct 19
'Momentum building' within C4X Discovery portfolio as it looks to license NRF-2 programme
-momentum-building-within-c4x-discovery-portfolio-as-it-looks-to-license-nrf-2-programme
  • 02 Sep 19
Small Cap Feast

SEC S.p.A. Admission is following a reverse takeover under Rule 14 by SEC S.p.A of Porta Communications plc, another AIM quoted company. No funds being raised. Due 4 September. Mkt cap c £9.9m. The merger will create a business with global fee income of around €80m and a host of PR agencies, including Newgate, Publicasity and Newington. The Group undertakes its main trade of lending as well as electricity generation through the operation of two solar farms.

Companies: SEE SRE C21 TEK C4XD HUR ABDP FARN EUZ

C4X Discovery Holdings PLC

Company Profile

  • Personnel
  • Clive Dix, CEO
  • Bradley Hoy, CFO

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on C4X Discovery Holdings PLC. We currently have 28 research reports from 4 professional analysts.

  • Open: 26.0p
  • Range Today: 26.0/26.0p
  • 52 Week: 25.0/48.0p
  • Daily Volume: 61.7k
  • Daily Liquidity: 0.03%
  • # Shares: 229.2m
  • Market Cap: £61.9m
  • Latest PE (hist):
  • Div Yield:

Latest News/RNS

(more news)
Date Source Announcement
28Apr22 07:00 RNS C4X Discovery - Half Year Results
19Apr22 07:00 RNS C4X Discovery - Notice of Results
28Feb22 17:30 RNS C4X Discovery - Exercise of Options, Issue of Equity and TVR
03Feb22 07:00 RNS C4X Discovery - Grant of Options and Directors Dealing
01Feb22 07:00 RNS C4X Discovery - Block listing Return
01Feb22 07:00 RNS C4X Discovery - Bhavna Hunjan Appointed as Chief Business Officer
24Jan22 16:09 RNS C4X Discovery - Holding(s) in Company
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    C4X Discovery Holdings PLC

  • Providers covering

    C4X Discovery Holdings PLC

  • 17 May 22
Confidence in profitable expansion rebuilding

2021 was a tough year which saw the non-repeat of highly profitable hand sanitiser sales, almost no Chinese sales and the impact of input/cost inflation. However, it successfully integrated 2 acquisitions, which enhance the portfolio and earnings quality, and locked in the planned synergies. With new distribution agreements (inc to China), and mitigations in place to claw back lost margin, VLG looks set to return to profitable growth. The platform is highly scalable and trades on just 5x EV/EBIT

Companies: Venture Life Group Plc
  • 17 May 22
First clinical evidence for LBP in asthma

MRx-4DP0004 is 4D Pharma’s oral, immunomodulatory, single strain Live Biotherapeutic product (LBP). The safety portion of this Phase 1/2 (Part A) met the primary endpoint of safety and tolerability, with five secondary endpoints qualitatively improved over the placebo arm. The data is being presented in poster session at the ATS meeting May 15-18, 2022.

Companies: 4d Pharma PLC
  • 23 May 22
LIBERUM: Futura Medical* - A deal the market has been waiting for


Companies: Futura Medical plc
  • 17 May 22
Bugs as drugs...and vaccines

4D Pharma is a pharmaceutical company developing Live Biotherapeutic Products (LBPs), a novel class of drug derived from the human gut microbiome. This differentiated approach focuses on leveraging the interactions of LBPs with host biology, underpinned by a proprietary MicroRx® platform. This has generated a strong clinical and preclinical pipeline of single strain LBPs targeting major diseases across multiple therapeutic area. A well flagged cash requirement overshadows the stock but the exper

Companies: 4d Pharma PLC
  • 06 May 22
Morning Note – 6 May 2022


Companies: SDI Group plc
  • 20 May 22
Cenkos: Healthcare Sector - Ward Round

Weekly round-up of AIM-listed healthcare news. Venture Life Group, GENinCode, Kromek, Alliance Pharma, Polarean Imaging, Benchmark Holdings, Ondine Biomedical, Verici Dx, Faron Pharmaceuticals, Avacta Group, Abingdon Health, Open Orphan, Belluscura, Hutchmed (China), Oxford Biodynamics

Companies: ANIC RUA CREO GENI HEIQ IHC IXI IUG OPTI SBTX VAL VLG

  • 16 May 22
Morning Note – 16 May 2022


Companies: Kromek Group Plc (KMK:LON)Synairgen plc (SNG:LON)
  • 16 May 22
CMD demonstrated broader opportunity set

Yourgene’s Capital Markets Day on 26/4 provided a strong illustration of the significant strategic progress the group has made in recent years. The pandemic was both a blessing and a curse for YGEN, delaying some opportunities, but catalysing others and leaving the group in a stronger net position than where it started. The building blocks are now in place and, as healthcare markets normalise globally, we believe Yourgene is poised for a period of extended growth, with multiple opportunities to

Companies: Yourgene Health Plc
  • 16 May 22
Hybridan Small Cap Feast 16/05/22

Dish of the day Joiners: No Joiners Today. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa intends to join the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Due 18th May 2022. EnSilica, intends to join AIM. EnSilica is a designer and supplier of mixed signal Application Specifi

Companies: EEE FARN FCAP HZM JLP NSCI SRE

  • 12 May 22
Continued growth and margin improvement prompt further upgrades

A positive AGM update confirms strong revenue growth has continued YTD and further margin improvement means management again expect EBITDA to be materially ahead of expectations. The business model is now settled, with additional distributors appointed in the US which should help drive further penetration into the Primary Care market there. China revenues were strong and with no sign yet of any slowdown, despite being cognisant of renewed lockdowns there. Gross margins have remained robust on po

Companies: Circassia Group PLC
  • 17 May 22
Cenkos: Venture Life Group Plc -- FY21 results, positive outlook

Venture Life Group has reported its results for FY21A, with revenues and adjusted EBITDA coming in ahead of our forecasts. Revenues, supported by two acquisitions, grew 9% to £32.8m with the acquisitions more than offsetting lost FY20A COVID-related sales and significantly reduced shipments to China. The gross margin was also affected by these factors, though also supported by higher margin acquisitions. Adjusted EBITDA grew 8%. Management have provided a positive outlook for FY22E, based on tra

Companies: Venture Life Group Plc
  • 19 May 22
SHORE CAPITAL - RUA Life Sciences - Cessation of coverage RYA, 42p - We are withdrawing our forecasts and ceasing research coverage


Companies: RUA Life Sciences Plc
  • 06 May 22
Omega Diagnostics - Placing raises £2.0m with Open Offer up to £2.0m

Omega Diagnostics has raised £2.0m, with up to £2.0m possible via an Open Offer to provide a bridge to the sale of the CD4 business and enable it to focus on the growth opportunities within its core business, Health & Nutrition. Having sold its Alva site in March for £1m, with a transitionary agreement put in place with Accubio until December 2022 to ensure the continued production of CD4 lateral flow tests, Omega has elected to sell the CD4 business, which would cost c.£1.5m to relocate to Ely

Companies: Omega Diagnostics Group PLC
  • 18 May 22
Hybridan Small Cap Feast 18/05/22

Dish of the day Joiners: Lekoil, the oil and gas exploration and production Company with a focus on Nigeria and West Africa has joined the Access Segment of the AQSE Growth Market. The Company was previously listed on AIM (LEK.L), however, Ordinary Shares have been suspended from trading on AIM since October 2021. Leavers: No Leavers Today. What’s cooking in the IPO kitchen? Psych Capital PLC, intends to list on the AQSE Growth Market. Psych operates the Psych Platform (a business-to-business ne

Companies: CZA AXL AEE CORA D4T4 EKF ORPH PWM PPH SYM

  • 19 May 22
Poised for multiple value inflection points

FY21 results were well-trailed and contain no surprises. The company continues to execute in line or ahead of plan and, following a £10m fundraise post-period end, is funded through a number of key inflection points. Investors can look forward to a number of these in the near term, including commercial launch and first revenues from first product Tuteva later this year. Rolling forward our risk-adjusted DCF results in a further increase in our TP to 76p (from 65p). we reiterate our Buy recommend

Companies: Verici Dx Plc